Did you know?

Exscientia, based in Oxford, England, is paying 50 million euros ($60.6 million) in a combination of cash and shares for the Vienna-based Allcyte, according to a company press release.This came just a few months after Recursion raised $436 million in an upsized IPO in April 2021 (Table 1). Exscientia, a pioneer in applying AI to small-molecule drug design, had a hefty IPO in ...In October 2021, Exscientia was floated on the Nasdaq stock market, raising $510 million, the largest initial public offering for a European biotech ever. From small beginnings, with just five staff, Exscientia now employs over 400 people.Date Filing Type Filing Description Download / View. November 9, 2023. 6-K. Report of Foreign Issuer. September 20, 2023. 6-K. Report of Foreign Issuer. August 10, 2023. 6-K.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comExscientia held an initial public offering of American Depository Shares last year and currently has a market value of $2.1 billion, according to data compiled by Bloomberg. Sanofi shares were up ...We would like to show you a description here but the site won’t allow us.Stock analysis for Exscientia Plc (EXAI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The Schrödinger Building Oxford Science Park, Oxford OX4 4GE . Phone: +44 (0) 1865 818941Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Exscientia anticipates submitting a Clinical Trial Application (CTA) by the end of 2022 and initiating a Phase 1/2 clinical trial in multiple solid tumour indications, including ovarian cancer, in the first half of 2023. The poster is available on Exscientia's website. About ExscientiaFind real-time EXAI - Exscientia PLC stock quotes, company profile, news and forecasts from CNN Business.Characterisation of EXS73565, a Potent and Selective MALT1 Inhibitor with Low Drug-drug Interaction Risk and Potential in Lymphoma. Event: European Society For Medical Oncology (ESMO) Congress. Published: 2023.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.May 24, 2023 · That made the stock quite an outlier, as the S&P 500 index slipped by 0.7% on the day. So what Exscientia, which harnesses AI in the discovery and development of pharmaceuticals, published its ... This results in a target price of $34.4 (12.74 x 2.7) based on the current share price. This is a high target in view of current market conditions where stocks with negative earnings are being ...OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most ...Company profile page for Exscientia Plc including stock price, company news, executives, board members, and contact information Like Recursion, Exscientia (NYSE: EXAI) uses AI in its approach to drug discovery.Unlike Recusion, Exscientia aims to develop bespoke drug solutions for patients. Exscientia was the first to bring ...Real time Exscientia Plc (EXAI) stock price quote, st2012. 481. Andrew Hopkins. https://www.exscien Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world’s oldest and most influential scientific society. Andrew is one of the UK’s most eminent science and technology business leaders, pairing pharmaceutical research with the … About Exscientia Stock. Founded 10 years ago, Exscientia describes i Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours. The clinical trial will evaluate the safety, efficacy and pharmacokinetics of ... Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)

Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.78% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.10 and a low of $4.95. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...Exscientia plc : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: EXAI | NasdaqRevenue: Revenue for the three and nine months ended September 30, 2023 was $10.8 million and $21.6 million respectively, compared to $7.7 million and $24.9 million for the three and nine months ...View the latest Exscientia PLC ADR (EXAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.May 26, 2023 · Shares of Exscientia ... The artificial intelligence (AI)-driven precision medicine biotech stock is up more than 47% so far this year. It closed last week at $6.04 a share, then rose to as high ...

What is Exscientia's stock price target for 2024? 3 brokers have issued twelve-month price targets for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $10.25 in the next year. This suggests a possible upside of 75.5% from the stock's current price.Die Exscientia Limited (spons. ADRs) Aktie wird unter der ISIN US30223G1022 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, Bats, NASDAQ Bsc, Gettex, Tradegate, Lang ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Exscientia PLC (ADR) Stock Price History. Exscientia PLC . Possible cause: Get the latest stock quote, price, volume, change, and historical data of Exscien.